期刊文献+

1H-MRS检测早期帕金森病纹状体、黑质的功能代谢 被引量:8

Metabolic changes of striatum and substantia nigra in patients with early Parkinson's disease demonstrated by 1H-MRS
下载PDF
导出
摘要 目的探讨1H-MRS检测早期帕金森病(PD)患者纹状体和黑质代谢变化的可能性。材料与方法 44例经临床确诊的双侧肢体症状不伴痴呆的早期PD患者纳入研究,32名年龄、性别等相匹配的健康志愿者作为对照组,两组均进行纹状体单体素1H-MRS及黑质多体素1H-MRS检查。PD患者33例获得纹状体MRS谱线,32例获得黑质MRS谱线;志愿者31名获得双侧纹状体MRS谱线,28名获得双侧黑质谱线。测量豆状核、黑质区域NAA、Cho、Cr及各参数比值,并进行比较分析。结果 PD组及对照组左右侧纹状体、黑质NAA、Cho、Cr各参数比值的差异均无统计学意义(P值均>0.05)。PD组纹状体NAA/Cr较对照组降低(P<0.05),其余各参数比值与对照组无明显差异(P>0.05);黑质各参数值两组间的差异无统计学意义(P值均>0.05)。结论 1H-MRS能检测双侧症状不伴痴呆的早期PD患者纹状体代谢异常,有助于早期PD的诊断。 Objective: To investigate whether 'H-MRS can be used to demonstrate the metabolic changes in striatum and substantia nigra for early Parkinson's disease (PD). Materials and Methods: Totally, 44 patients with early Parkinson's disease having bilateral symptoms but without dementia were enrolled. Thirty-two age and sex-matched volunteers were included as normal controls. ~H-MRS using single- voxel PRESS for the striatum and multiple-voxel PRESS for the substantia nigra were performed. MRS data were successfully obtained from the striatum in 33 patients and the substantia nigra in 32 patients, and respectively from 31 and 28 volunteers. The metabolite contents, including N-acetylaspartete (NAA), Choline (Cho), Creatinine (Cr) and their relative ratios were analyzed and compared. Results: No significant differences were found for each ratio of metabolite contents between right and left in striatum and substantia nigra either in the patients or in the controls (P〉0.05). The NAA/Cr ratio of the striatum was lower in the PD patients than that in controls (P〈0.05), but no significant differences were found in other ratios (P〉0.05). In the substantia nigra, there were no significant differences for all metabolite content ratios between the two groups (P〉0.05). Conclusions: 1H-MRS can be used to detect the metabolic abnormality in striatum for early PD with bilateral symptoms without dementia, which is helpful for the early diagnosis of PD.
出处 《磁共振成像》 CAS CSCD 2015年第7期481-485,共5页 Chinese Journal of Magnetic Resonance Imaging
基金 广东省科技厅基金项目(编号:2012B031800002)
关键词 帕金森病 磁共振波谱学 黑质 纹状体 Parkinson disease Magnetic resonance spectroscopy Substantia nigra Corpus striatum
  • 相关文献

参考文献5

二级参考文献38

  • 1黄海东,邓敬兰,宦怡,杨春敏,葛雅丽,赵海涛.脑质子磁共振波谱在早期帕金森病诊断中的价值[J].实用放射学杂志,2004,20(6):486-488. 被引量:7
  • 2孟海伟,刘树伟,侯中煜,吴风霞,冯蕾,程葆华,李振平.质子磁共振波谱在帕金森病大鼠模型中的应用研究[J].山东大学学报(医学版),2005,43(9):769-772. 被引量:2
  • 3苗重昌,何银,史良玉.氢质子磁共振波谱对帕金森氏病的诊断价值[J].河北医学,2006,12(11):1114-1116. 被引量:3
  • 4MARTIN W R. MR spectroscopy in neurodegenerative disease[J]. Mol Imaging Biol, 2007, 9(4) : 196-203.
  • 5CLARKE C E, LOWRY M. Systematic review of proton magnetic resonance spectroscopy of the striatum in Parkinsonian syndromes[J]. Eur J Neurol, 2001, 8(6): 573.
  • 6CHOI I Y, LEE S P, GUILFOYLE D N, et al. In vivo NMR studies of neurodegenerative diseases in transgenie and rodentmodels[J]. Neurochem Res, 2003, 28(7):987-1001.
  • 7CHOI J K, DEDEOGLU A, JENKINS B G. Application of MRS to mouse models of neurodegenerative illness[j]. NMR Biomed, 2007, 20(3): 216-203.
  • 8PODELL M, HADJICONSTANTINOU M, SMITH M A, et al. Protonmagnetie resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of Parkinsonism[J]. Exp Neurol, 2003, 179(2):159- 166.
  • 9VAN VLIETA S A, BLEZER E L, JONGSMA M J. Exploring the neuroproteetive effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy[J]. Brain Res, 2008, 16 (1189) : 219-281.
  • 10Clarke CE, Lowry M. Systematic review of proton magneticresonance spectroscopy of the striatum in parkinsonian syndromes [J]: EurJ Neurol, 2001,8:573-577.

共引文献631

同被引文献66

  • 1闫卫红,程焱,高硕,蔡莉,李彦生,李大成,邢喜玲.轻型帕金森病D_2受体的PET显像[J].中华神经科杂志,2006,39(6):374-378. 被引量:5
  • 2张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 3Samii A,Nutt JG,Ransom BR.Parkinson’s disease[J].Lancet,2004,363:1783-1793.
  • 4Martin WR.Magnetic resonance imaging and spectroscope in Parkinson disease[J].Adv Neurol,2001,86:197-203.
  • 5Pavese N,Rivero-Bosch M,Lewis SJ,et al.Progression of monoaminergic dysfunction in Parkinson’s disease:a longitudinal18Fdopa PET study[J].Neuroimage,2011,56:1463-1468.
  • 6Sossi V,Dinelle K,Jivan S,et al.In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using11C-methylphenidate PET[J].J Nucl Med,2012,3:813-822.
  • 7Okamura N,Villemagne VL,Drago J,et al.In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with18F-AV-133[J].J Nucl Med,2010,51:223-228.
  • 8Lin SC,Lin KJ,Hsiao IT.In vivo detection of monoaminergic degeneration in early Parkinson disease by18F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET[J].J Nucl Med,2014,55:73-79.
  • 9Shinto AS,Antony J,Kamaleshwaran K,et al.Correlative99mTclabeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease[J].World J Nucl Med,2014,13:178-183.
  • 10Van Laere K,Clerinx K,D'Hondt E,et al.Combined striatal binding and cerebral influx analysis of dynamic11C-raclopride PET improves early differentiation between multiple-system atrophy and parkinson disease[J].J Nucl Med,2010,51:588-595.

引证文献8

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部